Early trial halted for advanced breast cancer treatment
NCT ID NCT04504331
Summary
This early-stage study aimed to find a safe dose for combining two drugs (infigratinib and tamoxifen) to treat advanced breast cancer with specific genetic changes. It enrolled only 4 participants before being terminated. The main goal was to identify side effects and determine if the combination could help control cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
Explore the condition pages connected to this study.